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The two axes of the renin–angiotensin system include the classical ACE/Ang II/AT1 axis
and the counter-regulatory ACE2/Ang-(1-7)/Mas1 axis. ACE2 is a multifunctional mono-
carboxypeptidase responsible for generating Ang-(1-7) from Ang II. ACE2 is important in
the vascular system where it is found in arterial and venous endothelial cells and arterial
smooth muscle cells in many vascular beds. Among the best characterized functions of
ACE2 is its role in regulating vascular tone. ACE2 through its effector peptide Ang-(1-7)
and receptor Mas1 induces vasodilation and attenuates Ang II-induced vasoconstriction.
In endothelial cells activation of the ACE2/Ang-(1-7)/Mas1 axis increases production of the
vasodilator’s nitric oxide and prostacyclin’s and in vascular smooth muscle cells it inhibits
pro-contractile and pro-inflammatory signaling. Endothelial ACE2 is cleaved by proteases,
shed into the circulation and measured as soluble ACE2. Plasma ACE2 activity is increased
in cardiovascular disease and may have prognostic significance in disease severity. In ad-
dition to its enzymatic function, ACE2 is the receptor for severe acute respiratory syndrome
(SARS)-coronavirus (CoV) and SARS-Cov-2, which cause SARS and coronavirus disease-19
(COVID-19) respectively. ACE-2 is thus a double-edged sword: it promotes cardiovascular
health while also facilitating the devastations caused by coronaviruses. COVID-19 is associ-
ated with cardiovascular disease as a risk factor and as a complication. Mechanisms linking
COVID-19 and cardiovascular disease are unclear, but vascular ACE2 may be important.
This review focuses on the vascular biology and (patho)physiology of ACE2 in cardiovascu-
lar health and disease and briefly discusses the role of vascular ACE2 as a potential mediator
of vascular injury in COVID-19.
Introduction
The renin–angiotensin system (RAS) plays a pivotal role in the regulation of blood pressure, electrolyte
and water homeostasis, vascular tone and cardiovascular and renal health [1]. It is a peptidergic system
comprising a circulating and a tissue component [2]. Activation is initiated with the release of liver-derived
angiotensinogen into the circulation, where it is cleaved by kidney-derived renin into angiotensin I (Ang I)
[3], which undergoes further cleavage to angiotensin II (Ang II) by angiotensin-converting enzyme (ACE),
expressed mainly in pulmonary endothelial cells (Figure 1). In addition to the classical Ang I/ACE/Ang
II pathway, an alternate pathway was identified when ACE2, a homologue of ACE, was discovered [4,5].
ACE2 hydrolyses multiple peptides, including Ang I and Ang II to produce Ang-(1-9) and Ang-(1-7)
respectively [6].
Ang II is the main effector peptide of the RAS and signals via Ang II type 1 (AT1R) and Ang II type
2 receptors (AT2R) [7]. Ang II binding to the AT1R leads to coupling of G proteins (Gi/Go, G12/G13 and
Gq/G11), second messenger signaling through Ca2+ and reactive oxygen species (ROS) generation with
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Figure 1. Mechanisms involved in the generation and catabolism of angiotensin peptides, including Ang-(1-7)
Renin converts angiotensinogen to angiotensin I, which is cleaved by ACE to generate angiotensin II. ACE2, PCP and PEP catalyse
the conversion of angiotensin II to angiotensin-(1-7). Angiotensin-(1-7) can also be formed from angiotensin I by ACE2, which
involves the production of the intermediate form angiotensin-(1-9) and its cleavage by ACE, NEP or PEP. Angiotensin II signals
through AT1 and AT2 receptor, while angiotensin-(1-7) signals through Mas1 and MrgD. ACE, angiotensin-converting enzyme;
ACE2, angiotensin-converting enzyme 2; AT1R, angiotensin II type 1 receptor; AT2R, angiotensin II type 2 receptor; NEP, neutral
endopeptidase; Mas1, Mas1 receptor; MrgD, Mas-related-G-protein-coupled receptor D; PCP, prolyl carboxypeptidase; PEP, prolyl
oligopeptidase; THOP, thimet oligopeptidase.
subsequent activation of downstream signaling molecules including myosin light chain kinase (MLCK), calcium
channels, phospholipases, Rho kinase, mitogen-activated protein kinases (MAPK), serine threonine kinases (PI3K,
Akt, PKC) and tyrosine kinases (c-Src, JAK/STAT, epidermal growth factor receptor (EGFR)) [8]. Ang II binding to
the AT2R induces endothelial nitric oxide synthase (eNOS) activation, nitric oxide (NO) generation, protein tyrosine
phosphatase activation and sphingolipid signaling leading to vasorelaxation, decreased vascular tone and natriure-
sis [9]. The major (patho)physiological actions of Ang II, including vasoconstriction, inflammation and fibrosis, are
mediated via AT1Rs [10,11]. In general, AT2R-mediated actions oppose those of the AT1R; however, the exact phys-
iological role of AT2Rs in humans still remains unclear.
Whereas ACE cleaves the decapeptide Ang I to the octapeptide Ang II, ACE2 cleaves Ang I and Ang II to form
Ang-(1-9) and Ang-(1-7), respectively [4,12]. ACE2 is a negative regulator of the RAS because it decreases Ang
II levels and increases Ang-(1-7) and Ang-(1-9), which are vasodepressor peptides that counteract the vasocon-
strictor actions of Ang II [13,1]. Beyond Ang I and Ang II, ACE2 has numerous biological substrates including
(des-Arg9)-bradykinin, an agonist of the B1 receptor, apelin-13, a vasoconstrictor and other non-RAS peptides in-
cluding kinetensin, dynorphin A and neurotensin [14]. Ang-(1-7) is also generated from Ang I by thimet oligopep-
tidase (THOP1), prolyl oligopeptidase (PEP) and neutral endopeptidase (NEP), while carboxypeptidase A and pro-
lyl carboxypeptidase (PCP) generate Ang-(1-7) from Ang II [15–17]. Ang-(1-7) signals mainly through receptor
Mas1 and to a lesser extent through Mas related G protein-coupled receptor D (MrgD) [18,19]. Activation of the
ACE2/Ang-(1-7)/Mas1 pathway has vasodilatory, anti-proliferative, anti-inflammatory and anti-fibrotic effects and
accordingly has been described as the counter-regulatory arm of the RAS, especially in the vascular system where
it protects against increased vascular tone and pathological remodelling and inflammation [20]. Accordingly, there
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is increasing interest in targeting ACE2/Ang-(1-7)/Mas1 as a vasoprotective strategy in cardiovascular disease. In
addition to its function as a master negative regulator of the RAS, ACE2 acts as the functional receptor for severe
acute respiratory syndrome (SARS) coronaviruses (SARS-CoV) including SARS-CoV-2, the cause of coronavirus
disease-19 (COVID-19) [21–23].
While ACE2 is widely expressed and has multiple functions influencing various (patho)physiological systems, this
review focuses primarily on ACE2 in the vascular system and discusses the role of Ang-(1-7) as the primary peptide
effector of ACE2. In addition, we briefly discuss the putative role of vascular ACE2 in the cardiovascular sequelae of
COVID-19. It should be highlighted that the field of vascular ACE2, SARS-CoV-2 and COVID-19 is still immature,
with many gaps in knowledge. Accordingly, here we only provide some introductory comments on vascular ACE2
and COVID-19. Further original research is needed for a comprehensive review on the topic.
ACE2-a primer
ACE2 shares ∼42% homology with ACE and similar to ACE is a transmembrane protein with the extracellular do-
main comprising catalytic function. In humans, ACE2 protein is encoded by the Ace2 gene on the X-chromosome and
is located near a quantitative trait locus linked to hypertension [24]. Unlike ACE, ACE2 does not cleave bradykinin,
and it is not inhibited by classical ACE inhibitors [4,25]. The membrane-bound ectodomain of ACE2 is cleaved by
tumour necrosis factor-alpha-converting enzyme (TACE/ADAM17), resulting in shedding of ACE2 into the circu-
lation [26]. This is the soluble form of ACE2 and can be measured in plasma. The relative amount of soluble ACE2
to membrane-bound ACE2 is very low, and the physiological role of soluble ACE2 still remains unclear, although it
may play a role in the degradation of circulating, but not tissue, Ang II to Ang-(1-7) [27]. Plasma ACE2 activity is low
in healthy individuals, possibly due to an endogenous inhibitor [28,29]. However, in cardiovascular disease shedding
of ACE2 is increased and plasma ACE2 levels and activity may be increased [30,31]. Plasma ACE2 levels are higher
in men than women in health and disease [32] and could relate to the fact that Ace2 is an X-linked gene that might
reflect sex-specific differences in control of ACE2 expression and activity.
ACE2 is a multifunctional protein. Beyond its catalytic function generating the peptides Ang-(1-9) and Ang-(1-7),
it has noncatalytic actions including the regulation of renal amino acid transport, control of intestinal neutral amino
acid transport, pancreatic insulin secretion and coronavirus receptor [33]. As the functional receptor of SARS-CoV
and SARS-CoV-2, ACE2 plays a critical role in the pathophysiology of SARS and COVID-19 [20–22]. ACE2 may
also be a signaling molecule involved in outside-in signalling [34,35]. The cytosolic domain possesses numerous
phosphorylation sites and interacts with calmodulin, which may inhibit shedding of the ectodomain [34,35]. ACE2
has a widespread distribution, and its biological functions likely relate to its expression pattern and activation state in
different tissues and organs.
Expression of ACE2 in the vascular system
ACE2 is ubiquitously expressed in human tissues in normal and pathological conditions. In the vascular system,
ACE2 is localized in arterial and venous endothelial cells and arterial smooth muscle cells in many organs (Table 1)
[12,36–45]. ACE2 protein has also been detected in human atherosclerotic arteries and vascular macrophages [36].
In patients with ischemic heart disease undergoing coronary artery bypass surgery, immunohistochemical analysis
showed abundant ACE2 positive cells in diseased vessels, particularly in the neo-intima and media, and in newly
formed angiogenic vessels and vasa vasorum, indicating a potential role for ACE2 in pathological conditions [38].
In the human heart, single nuclei RNA sequencing demonstrated cell type-specific expression of ACE2, which was
identified in cardiomyocytes, fibroblasts, endothelial cells, smooth muscle cells and pericytes [46]. In patients with
heart disease, expression of ACE2 was increased in cardiomyocytes and endothelial cells, whereas fibroblast ACE2 ex-
pression was reduced compared with healthy controls [46]. Cardiomyocyte ACE2 content is also increased in patients
with aortic stenosis and heart failure [47].
Disruption of ACE/ACE2 balance in the cardiovascular system has been implicated in hypertension [28]. How-
ever, ACE2 as a potential therapeutic target in hypertension has been disappointing because ACE2 inhibitors do not
increase blood pressure significantly in experimental models and agents that enhance ACE2 activity, including re-
combinant human ACE2 (rhACE2), have failed to consistently reduce blood pressure in hypertensive models and
humans [28,48].
Regulation of vascular ACE2
Mechanisms that control ACE2 in the cardiovascular system are complex and multifactorial. ACE is regulated at the
transcriptional and post-transcriptional levels. Molecular elements such as miRNAs (miR-421) [49], transcription
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Carotid artery ACE2 mRNA Human [36]
Colon and Brain ACE2 protein Human [37]
Liver and Spleen ACE2 protein Human [37]
Oral mucosa and small intestine ACE2 protein Human [37]
Heart, kidney and Testis ACE2 protein Human [12]
Heart ACE2 mRNA, protein and activity Rat [38]
Heart ACE2 protein and mRNA Human [38]
Pancreas ACE2 protein Human [39]
Thyroid and parathyroid gland ACE2 protein Human [39]
Adrenal gland and fallopian tube ACE2 protein Human [39]
Umbilical cord ACE2 protein and mRNA Human [40]
Lungs ACE2 protein Rat [41]
Vasa Vasorum ACE2 protein Human [42]
Eye Mas1 protein and mRNA Mouse [43]
Lungs Mas1 mRNA and protein Human [44]
Brain Mas1 mRNA Rat [45]
Abbreviations: ACE-2, angiotensin-converting enzyme 2; Mas1, Mas1 receptor; mRNA, messenger RNA
factors (C/EBPβ) [50] and signalling molecules (sirtuin-1) [51] have been shown to influence ACE2 expression.
ACE2 is also regulated by Ang II through AT1 and AT2 receptors. Increased Ang II/AT1R signaling through ERK1/2
and p38MAPK in cardiovascular and kidney tissue down-regulates ACE2 while expression of ACE is increased [52].
On the other hand, activation of AT2R increases expression and activity of ACE2 in endothelial cells [53].
Aldosterone, through mineralocorticoid receptor activation, may also regulate ACE2 [54]. Aldosterone does not
seem to influence ACE2 enzymatic activity but influences its expression. In neonatal cardiomyocytes, aldosterone,
but not Ang II, decreased mRNA expression of ACE2, with an associated increase in ACE expression [55]. This
imbalance between ACE2 and ACE may contribute to pathological cardiovascular remodelling. These in vitro find-
ings were recapitulated in in vivo studies where aldosterone infusion in rats induced a significant decrease in renal
ACE2 expression, particularly in the brush border membrane of the proximal convoluted tubules [56]. This was
mediated through mineralocorticoid receptor signalling via proinflammatory NFkB pathways. Spironolactone treat-
ment normalised ACE2 expression in aldosterone-treated rats, supporting the role of mineralocorticoid receptors in
aldosterone-mediated ACE2 regulation [56].
Besides humoral mediators, vascular ACE2 is regulated by mechanical factors such as shear stress and stretch. In
vascular smooth muscle cells, stretch increased the promoter activity of ACE2 but did not affect its mRNA stability,
indicating that mechanical stretch influences ACE2 primarily at the transcriptional level [57]. Molecular processes
underlying this involve activator protein-1 (AP-1), which directly interacts with ACE2. NF-κB seems to be a negative
regulator of ACE2 in an indirect manner, since the ACE2 promoter site lacks a binding site for NF-κB. PKCβII and
JNK1/2 have also been implicated in stretch-mediated ACE2 expression. It has been proposed that physiological
stretch up-regulates vascular smooth muscle cell ACE2, which inhibits proliferation and migration, likely through
increased Ang-(1-7)/Mas1 signalling [57].
Vascular ACE2 regulation and inhibitors of the RAS
Based on the premise that inhibition of the ACE/Ang II/AT1R pathway potentiates ACE2 actions and activation of
the counter-regulatory system, it has been suggested that drugs that inhibit the RAS will influence ACE2 expression
and activity [58–60]. Clinical studies demonstrated increased expression of ACE2 in cardiomyocytes and vascular
cells in hearts from patients who were treated with ACE inhibitors (ACEi) compared with those treated with an-
giotensin receptor blockers (ARB) [59]. Moreover, the ACE:ACE2 ratio was four-fold higher in ACEi-treated patients
versus healthy individuals and may represent an imbalance between the injurious and protective arms of the RAS. In
ACEi-treated patients with coronary artery disease, Ang-(1-7) production was not altered, indicating lack of ACE2
modulation [59,60]. Similarly, in cross-sectional studies involving patients with heart failure, aortic stenosis, coro-
nary artery disease and atrial fibrillation, the use of ACEi or ARBs did not affect plasma ACE2 activity in comparison
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Figure 2. Schematic depicting the opposing effects of ACE/AngII/AT1R axis and ACE2/Ang-(1-7)/Mas1 axis in the
vasculature
Increased signalling through the ACE/AngII/AT1R axis promotes vascular injury while signalling through the ACE2/Ang-(1-7)/Mas1
axis leads to vasoprotection from the injury caused by ACE/AngII/AT1R axis stimulation. ACE, angiotensin-converting enzyme;
ACE2, angiotensin converting enzyme two; Ang II, angiotensin two; Ang-(1-7), angiotensin 1 to 7; AT1R, angiotensin two type one
receptor; Mas1, mas1 receptor.
with untreated patients [61–63]. In contrast, other studies in patients with hypertension showed that olmesartan, but
not losartan, candesartan, valsartan or telmisartan, increased urinary ACE2, indicating a possible drug-specific effect
[64].
In rodent models of cardiovascular injury, ACEi and ARBs have been associated with both up-regulation and
down-regulation of circulating and cardiovascular ACE2 [65–69]. Early studies in rodents showed that ACEi and
ARBs enhance tissue ACE2 expression and increase plasma Ang-(1-7) levels. Studies in experimental models of hy-
pertension, coronary artery ligation, atherosclerosis and diabetes, reported that ACEi and ARB treatment increases
ACE2 gene expression, plasma ACE2 levels and ACE2 activity [70]. Based on these findings, it was suggested that
beneficial clinical effects of ACEi and ARBs may relate, at least in part, to inhibition of the ACE/Ang II pathway
and activation of the ACE2/Ang-(1-7) pathway [69,70]. Supporting this, experimental studies showed that the Mas1
receptor antagonist (A779) blocked ACE2/Ang-(1-7) responses of ACEi and ARBs [71]. While there is strong evi-
dence that inhibitors of the RAS increase ACE2 expression at the gene level in vessels, heart and kidneys, this has
not been consistently demonstrated at the protein level. The functional significance of this is unclear and reflects the
complexity of the ACE2 system.
In addition to ACEis and ARBs, mineralocorticoid receptor antagonists have been shown to influence ACE2 ex-
pression. Spironolactone and eplerenone increase levels of ACE2 in plasma samples from patients with heart failure as
well as in heart tissue from experimental models of cardiovascular disease [72]. These findings suggest that beneficial
effects of mineralocorticoid receptor antagonists may be mediated, at least in part, by up-regulating ACE2 and the
vasoprotective arm of the RAS.
Functions of vascular ACE2
The exact physiological function of vascular ACE2 is still unclear, but it may be an important regulator of normal
endothelial and vascular smooth muscle cell function by fine-tuning and modulating vasoinjurious effects of Ang
II (Figure 2). In pathological conditions, vascular ACE2 may play a role in preventing pathological vascular remod-
elling. In cultured human endothelial cells, activation of endogenous ACE2 inhibits Ang II-induced phosphorylation
of ERK1/2 and c-Src, reduces Nox-derived ROS generation and increases phosphorylation of eNOS and production
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of NO, processes that promote vasorelaxation [73,74]. Deletion of vascular smooth muscle cell ACE2 leads to pheno-
typic switching to a proliferative and pro-inflammatory state [75], processes that are reversed or prevented in cells in
which ACE2 is up-regulated [76]. In human vascular smooth muscle cells, ACE2-derived Ang-(1-7) attenuates Ang
II-mediated proliferation and inhibits vascular calcification and atherosclerosis [76,77].
ACE2 has also been shown to influence the function of endothelial progenitor cell-derived exosomes, especially
related to phenotypic de-differentiation of vascular smooth muscle cells. In co-culture experiments with vascular
smooth muscle cells, exosomes released from ACE2-expressing endothelial progenitor cells reduced proliferation, mi-
gration and pro-inflammatory effects of Ang II [78]. These ACE2-dependent processes attenuated Ang II-stimulated
synthetic phenotypic switching through molecular events that downregulate NF-kB, thereby maintaining vascular
smooth muscle cell function in its normal state [78].
ACE2 and vascular pathophysiology in experimental models
Transgenic models have revealed the importance of vascular ACE2 in (patho)physiological conditions. One of the
most important studies interrogating the specific role of vascular ACE2 in intact systems was that of Rentzsch and
colleagues [79], where human ACE2 was expressed in a vascular smooth muscle cell-specific manner in spontaneously
hypertensive stroke prone rats (SHRSP). In these transgenic hypertensive rats, amplification of vascular smooth mus-
cle cell ACE2 was associated with significantly reduced blood pressure, decreased vasoconstrictor responses to Ang
II and normalization of endothelium-dependent vasorelaxation, effects that were blocked by treatment with an ACE2
inhibitor [80]. Similar observations were made in lentiviral overexpression of ACE2 in spontaneously hypertensive
rats (SHR) [80]. In SHR treated with the ACE2 activator xanthenone, development of hypertension was attenuated,
and vascular remodelling was prevented [81]. SHR and Ang II-infused rats treated with rhACE2 had reduced blood
pressure, decreased cardiovascular and renal oxidative stress, and suppressed pathological cardiac remodelling [82].
Together these findings suggest that in hypertension increased vascular ACE2 activity reduces blood pressure likely
through a combination of increased degradation of Ang II and augmented Ang-(1-7) production, which improve vas-
cular function. In Ang II-induced hypertension in mice, pretreatment with rhACE2 decreased blood pressure through
processes that enhanced Ang II degradation rather than by increasing Ang-(1-7) levels [27]. Supporting these find-
ings, genetic ablation of systemic ACE2 in C57BL/6 mice resulted in reduced NO bioavailability, increased oxidative
stress and vascular dysfunction leading to significant elevation in blood pressure [83].
Vascular ACE2 may be particularly important in cardiovascular disorders associated with inflammation, fibrosis
and remodelling. In atherosclerosis-prone ApoE knockout mice, genetic deletion of ACE2 accelerates vascular in-
flammation and plaque accumulation [84]. In rabbit aortic segments, ACE2 overexpression inhibited development
of early atherosclerotic lesions by suppressing the proliferation and migration of vascular smooth muscle cells and by
improving endothelial function [85. These studies indicated that the anti-atherosclerotic actions of ACE2 may result
from reduced Ang II levels, increased Ang-(1-7) production, decreased ACE activity and down-regulation of AT1R
signalling [84,85].
A vasoprotective role of ACE2 has also been demonstrated in pulmonary hypertension. In monocro-
taline (MCT)-induced pulmonary hypertension in rats, oral administration of ACE2 bioencapsu-
lated in plant cells attenuated the development and progression of pulmonary hypertension and pre-
vented pulmonary vascular remodelling [86]. Chronic treatment with a synthetic ACE2 activator
1-[2-(dimetilamino)etil]amino]-4-(hidroximetil)-7-[(4-metilfenil)sulfonil]oxi]-9H-xantona-9 (XNT) attenu-
ated MCT-induced pulmonary hypertension in rats with associated reduction in vascular wall thickness [87].
Pharmacological blockade of Mas1 receptor eliminated the cardioprotective effects of XNT, indicating that XNT
elicits its protective effects primarily through the Ang-(1-7)/Mas1 pathway.
ACE2 and vascular disease in humans
ACE2 mRNA and protein have been demonstrated in human atherosclerotic vessels, aortic aneurysms and coronary
arteries in patients with heart failure [88–90]. ACE2 is expressed in both early and advanced atherosclerotic lesions
[36]. While the content of ACE2 does not change during atherogenesis, ACE2 activity is lower in advanced plaques
versus early atherosclerotic lesions. These findings suggest that ACE2 regulation changes during atherogenesis and
that the vasoprotective function of ACE2 may be blunted with disease progression.
Vascular ACE2 has been identified in pathological vascular remodelling. In patients with bicuspid aortic valve, the
ascending aorta is dilated, and this is associated with increased expression and activity of ACE2, findings that were
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recapitulated in murine models [88]. In this context, ACE2 up-regulation was considered as a compensatory mech-
anism. In human abdominal aortic aneurysms, ACE2 was identified in the intima, media and adventitial inflam-
matory cells [89]. Supporting these human findings, ACE2 deficiency in murine models promoted Ang II-induced
development of aneurysms, effects that were prevented when ACE2 activity was increased pharmacologically with
diminazine aceturate (DIZE) [89]. Hence therapeutic stimulation of ACE2 may protect against vascular remodelling
in aortic disease and may have benefit in patients with aortic aneurysms.
Endothelial ACE2 shedding, plasma soluble ACE2 and
clinical implications
Shedding of ACE2 from endothelial cells by proteases releases the catalytically active ectodomain into the blood as
soluble ACE2, which can be measured in plasma [28,29]. Clinical studies have shown that plasma ACE2 activity
is increased in patients with hypertension, diabetes mellitus and chronic kidney disease [28]. However, some clin-
ical studies failed to show increased plasma ACE2 activity in hypertension, while others showed decreased soluble
ACE2 activity [28,91]. In pulmonary arterial hypertension plasma ACE2 activity was shown to be reduced [91]. This
prompted a clinical study to assess whether human ACE2 therapy would improve pulmonary arterial hypertension.
A single infusion of rhACE2 GSK2586881 resulted in significant improvement in cardiac output and pulmonary
vascular resistance, suggesting that ACE2 upregulation may be a potential therapeutic strategy [91,92].
ACE2 shedding also occurs in healthy states. Isolated human CD34+ cells from healthy individuals, when exposed
to hypoxic conditions, resulted in ACE2 ectodomain shedding [93]. This was further confirmed when blood flow
restriction stimulated mobilization of hematopoietic stem/progenitor cells and increased circulating ACE2 levels in
healthy subjects [94]. Thus ACE2 shedding may represent a physiological response to stress, which may become
dysregulated in pathological conditions.
The functional role of soluble ACE2 is still unclear but may be a biomarker of underlying vascular stress or car-
diovascular disease [47]. A recent association study examining the relationship between soluble ACE2 and plasma
proteins revealed that plasma ACE2 associates with signaling proteins linked to clathrin-mediated endocytosis, actin
cytoskeleton, eukaryotic initiation factor 2 (EIF2), protein ubiquitination and viral exit from host cells [90]. These
proteins are involved in cellular endocytosis, exocytosis and intracellular trafficking of signaling molecules and may
reflect cell damage and dysfunction in cardiovascular disease [90].
Ang-(1-7)/Mas1 and vascular function
Ang-(1-7) is the major downstream peptide generated from Ang II by ACE2 catalytic activity. The majority of ACE2
vascular effects are mediated by Ang-(1-7) [95]. Ang-(1-7) functions in opposition to Ang II and in the vasculature
promotes dilation [1]. Ang-(1-7) is anti-proliferative, anti-fibrotic, anti-inflammatory and anti-angiogenic, thereby
maintaining vascular integrity and promoting vascular health [95,96]. These effects are mediated via the G protein
coupled receptor Mas1, which signals through multiple pathways, including activation of Akt, increased NO genera-
tion, decreased ROS generation, and inhibition of Ang II-stimulated signalling pathways [1,6,73,74,95].
Vasodilation
Vasodilation is the best characterized vascular action of Ang-(1-7) and is evident in large conduit vessels, resistance
arteries and microvessels [96,97]. Ang-(1-7) synergistically increases vasodilation induced by bradykinin and ghrelin,
and attenuates agonist-induced vasoconstriction [1,98]. While experimental studies clearly support a vasodilatory
action of Ang-(1-7), this is less evident in human vessels. Some studies failed to show vasodilation in response to
Ang-(1-7) in the forearm circulation of normotensive subjects and patients with hypertension [99,100], while others
reported a dose-dependent augmentation of bradykinin vasodilation by Ang-(1-7) in forearm resistance vessels in
healthy men, confirming the bradykinin-potentiating effect of Ang-(1-7) identified in experimental models [101]. In
the forearm of normotensive patients as well as in mammary arteries in vitro Ang-(1-7) attenuates the vasoconstrictor
effect of Ang II, but not noradrenaline [102,103].
Antiproliferative and antifibrotic effects
In vascular smooth muscle cells, Ang-(1-7) opposes the mitogenic actions of Ang II by inhibiting activation of growth
signalling pathways such as MAP kinases [104,105]. Ang-(1-7)/Mas1 also inhibits transactivation of growth factor
receptors, such as EGFR, resulting in decreased activation of downstream signalling pathways involved in vascular
smooth muscle cell proliferation and vascular hypertrophy [106]. In response to vascular injury, Ang-(1-7) reduces
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neointimal formation and pathological vascular remodelling [107]. In atherosclerotic prone ApoE knockout mice,
Ang-(1-7) and AT1R blockade with losartan improved endothelial function, attenuated macrophage infiltration and
inhibited vascular smooth muscle cell proliferation and migration [108]. In addition, Ang-(1-7) prevents vascular
calcification and aneurysm formation by inhibiting osteogenic transition of vascular smooth muscle cells [109].
Haematopoietic stem/progenitor cells and vascular repair
In addition to directly influencing vascular function, the ACE2/Ang-(1-7)/Mas1 system activates haematopoietic
stem/progenitor cells, important in vascular repair [110–114]. ACE2/Ang-(1-7)/Mas1 activation promotes vasorepar-
ative properties of vascular progenitor cells and reverses reparative dysfunction in pathological conditions [113–118].
In a mouse model of Type 2 diabetes, Ang-(1-7) treatment increased bone marrow and circulating levels of endothelial
and mesenchymal stem cells [114]. Similar favourable responses were observed in a rat model of myocardial infarc-
tion treated with Ang-(1-7) and in a mouse model of ischaemic stroke where transfusion of lentivirus-ACE2-primed
endothelial progenitor cells increased angiogenesis and cerebral microvascular density [115,116]. In vitro studies
showed that activation of the ACE2/Ang-(1-7)/Mas1 axis stimulates vascular repair functions of CD34+ cells and
enhances the reparative function of dysfunctional endothelial progenitor cells in diabetes [117].
Ang-(1-7) signalling in vascular cells
Endothelial cells, NO and prostacyclin production
Ang-(1-7)-induced NO release by the post-translational regulation of eNOS (phosphorylation at Ser1177 and dephos-
phorylation at Thr495) is widely accepted as the primary event underlying vasoprotective effects of the peptide [1]
(Figure 3). Wortmannin (a phosphatidylinositol 3-kinase (PI3K) inhibitor) blocked Ang-(1-7)-mediated activation of
eNOS (Ser1177 phosphorylation) indicating that Ang-(1-7) regulates eNOS via Akt-dependent pathways. Ang-(1-7)
also counter-regulates Ang II actions in endothelial cells by reducing Ang II-stimulated activation of c-Src, ERK1/2
and Nox by enhancing SHP-2 phosphorylation [73,74,95]. In human umbilical vein endothelial cells (HUVEC),
Ang-(1-7) ameliorated Ang II-induced senescence by increasing the expression of the anti-ageing protein ‘Klotho’
and activation of the antioxidant, nuclear factor-erythroid-2-related factor (Nrf2)/haem-oxygenase 1 pathway [119].
It also blunted Ang II-induced expression of endoplasmic reticulum stress markers (p-eIF2α, ATF-6, CHOP, Grp78,
ATF4) and amplified NO production to maintain endothelial cell function [120]. In human cerebral endothelial cells,
Ang-(1-7) inhibited Ang II-stimulated ROS production, pro-apoptotic activity and reduced NO levels [121]. Fur-
thermore, protective effects of Ang-(1-7) against other stress inducers, such as thrombin, have been demonstrated in
endothelial cells [122].
In addition to regulating production of the vasodilator NO, Ang-(1-7) selectivity increases prostaglandin
synthesis [123]. Chronic infusion of Ang-(1-7) in SHR increased urinary excretion of prostaglandin E2 and
6-keto-prostaglandin F1α and induced diuresis, natriuresis, and decreased blood pressure [124]. In endothelial cells,
Ang-(1-7) stimulates the production of vasodilator prostacyclins via activation of PLA2 and CaM kinase II/ MAP
kinase [123], and in vascular smooth muscle cells prostacyclins play a role in Ang-(1-7) antiproliferative actions
[123,125].
Vascular smooth muscle cells and Ang-(1-7) signalling
Ang II is a potent vasoconstrictor that stimulates proliferation, inflammation, fibrosis and migration of vascular
smooth muscle cells, processes involved in vascular remodelling in pathological conditions. It is now clear that
Ang-(1-7) counteracts these actions by negatively regulating Ang II signaling [125–128]. In vascular smooth mus-
cle cells, Ang-(1-7) opposes Ang II-stimulated pro-oxidative and proliferative signaling, reduces phosphorylation of
c-Src, MAPKs and inhibits activation of Nox [105] (Figure 3). Ang-(1-7) attenuates Ang II-induced contraction by
inhibiting RhoA/ROCK2 signaling and phosphorylation of moesin and myosin light chain [126]. Other signaling
pathways influenced by Ang-(1-7) in vascular smooth muscle cells include NF-κB, IkBα, MAPK, and matrix metal-
loproteinases [127,128].
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Figure 3. Vascular signalling of Ang-(1-7)/Mas1 in endothelial cells and vascular smooth muscle cells
In endothelial cells, Ang-(1-7) activates eNOS via AKT to produce nitric oxide. Ang-(1-7) also stimulates production of vasodila-
tors such as prostacyclin (PGI2) and prostaglandin (PGE2) via enhancement of phospholipase A2 (PLA2) activity and arachidonic
acid (AA) release. Ang-(1-7) via Mas1 counter-regulates Ang II effects by increasing expression of anti-ageing protein klotho which
consequently activates Nrf2/HO-1 pathway and activation of c-Src, ERK1/2 and NADPH oxidase (Nox) by enhancing SHP-2 phos-
phorylation. In smooth muscle cells, Ang-(1-7) via Mas1 receptor opposes Ang II-induced contraction and oxidative stress by
attenuating RhoA/ROCK2 signalling, PLC and NADPH activation. Ang-(1-7) also suppresses Ang II-induced proliferation and in-
flammation by inhibiting MAPKs (ERK1/2, p38MAPK and JNK), MMP-8 and NFκB signalling. AKT, serine threonine specific protein
kinase; Ang II, angiotensin II; Ang-(1-7), angiotensin-(1-7); AT1R, angiotensin two type one receptor; ERK1/2, extracellular regulated
kinase one and two; HO-1, haem oxygenase one; JNK, c-Jun N-terminal kinases; MAPK, mitogen-activated protein kinase; Mas1,
mas1 receptor; MMP-8, matrix metalloproteinase 8; NADPH, nicotinamide adenine dinucleotide phosphate; NFkB, nuclear factor
kappa B; Nrf2, nuclear factor erythroid 2-related factor 2; PLC, phospholipase C; RhoA/ROCK2, RAAS homolog family member
A/Rho associated coiled-coil containing protein kinase 2; ROS, reactive oxygen species; SHP-2, small heterodimer partner 2.
Fibroblasts and Ang-(1-7) signalling
Studies in fibroblasts have also shown protective effects of Ang-(1-7). In renal interstitial fibroblasts, Ang-(1-7)
significantly decreased aldosterone-induced pro-fibrotic signaling [129]. In cardiac fibroblasts from Sprague Daw-
ley rats, Ang-(1-7)/Mas1 activated SHP-1, a redox-sensitive protein, and inhibited Ang II-induced phosphory-
lation of c-Src and its downstream signaling molecules ERK1/2, α-SMA and TGF-β [130]. Metabolomic stud-
ies in primary cardiac fibroblasts, demonstrated that Ang-(1-7) blunted Ang II-induced signaling by inhibiting
calcium/calmodulin-dependent protein kinase II delta (CaMKIIδ), Nox4, CTGF and ERK1/2 [131].
ACE2/Ang-(1-7) and vascular remodelling
Vascular remodelling is a complex process involving collagen deposition, fibrosis, inflammation, calcification and
endothelial dysfunction and occurs with normal ageing and in response to injury and disease. In pathological con-
ditions such as hypertension, atherosclerosis and diabetes mellitus, vascular remodelling is accelerated leading to
target organ damage [132]. Studies in ACE2 knockout mice showed augmented vascular stiffness, worsening of vas-
cular injury and potentiation of Ang II effects on oxidative stress, apoptosis and vascular smooth muscle cell phe-
notypic switching, while ACE2 overexpression inhibited vascular proliferation vascular hypertrophy and improved
endothelium-dependent vasorelaxation [75,84,133,134]. Moreover, rhACE2 prevented Ang II-induced vascular re-
modelling through processes involving JAK-STAT-SOCS signaling [76]. Many of the vasoprotective effects of ACE2
were recapitulated by up-regulation of the Ang-(1-7)/Mas1 system, while pharmacological inhibition or gene deletion
of Mas1 prevented ACE2/Ang-(1-7) beneficial effects [135]. In particular, in Mas1−/− mice acetylcholine-induced
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vascular relaxation is blunted, and mice exhibit endothelial dysfunction, increased mean arterial blood pressure,
cardiac dysfunction, reduced NO production, and increased oxidative stress [135,136]. There is thus convincing
pre-clinical evidence that the ACE2/Ang-(1-7)/Mas1 axis negatively regulates Ang II and that it is vasoprotective,
highlighting it as a potential therapeutic target in cardiovascular disease, especially in conditions associated with
activation of the RAS.
ACE2/Ang-(1-7)/Mas1 and vascular inflammation
Several studies have shown that the ACE2-Ang-(1-7)-Mas1 axis has anti-inflammatory properties in vascular injury
[137]. In vitro studies in human aortic smooth muscle cells demonstrated that Ang-(1-7) counteracts inflammatory
effects of Ang II by inhibiting iNOS, Nox and pro-inflammatory signaling pathways [138]. In human and rabbit en-
dothelial cells, anti-inflammatory effects of Ang-(1-7) involve lectin-like oxidized low-density lipoprotein receptor-1
(LOX-1) [139]. In vivo studies support the anti-inflammatory role of Ang-(1-7). In a mouse model of atherosclerosis,
chronic Ang-(1-7) treatment inhibited early atherosclerotic lesion formation by protecting endothelial function and
inhibiting the inflammatory response [140].
ACE2/Ang-(1-7)/Mas1, oxidative stress, antioxidants and
vascular function
Many of the molecular processes that underlie vascular injury and inflammation in pathological conditions involve
Ang II-induced activation of redox-sensitive pathways and oxidative stress [141]. The ACE2/Ang-(1-7)/Mas1 axis
counter-regulates oxidative damage in the vascular system by reducing Nox-mediated ROS production and increas-
ing antioxidant capacity [142,143]. In renal arteries from diabetic patients and in conduit and resistance arteries from
diabetic mice activation of ACE2/Ang-(1-7) improved endothelial function by decreasing oxidative stress through
processes that down-regulate Nox2 and up-regulate antioxidant enzymes [142]. Similar Nox2/ROS actions have been
observed in Ang II-stimulated brain microvascular endothelial cells, where Ang-(1-7) opposed pro-apoptotic actions
of Ang II by reducing Nox2 expression and decreasing ROS formation [121]. Other Nox isoforms, including Nox2 and
Nox4, are also modulated by ACE2/Ang-(1-7) [144]. In a model of ischaemic stroke, Ang-(1-7)-induced neuropro-
tection was associated with decreased Nox1 expression [145]. In diabetic SHR, Ang-(1-7) treatment improved renal
function by inhibiting the Nox4/ROS system [146] and in a mouse model of cardiac hypertrophy AVE 0991, a non-
peptide Ang-(1-7) analogue, prevented left ventricular hypertrophy and improved heart function by down-regulating
Nox2 and Nox4 and decreasing oxidative stress [147]. In addition, ACE2 overexpression in endothelial progenitor
cells decreased Nox4 expression and reduced ROS production [144]. These findings suggest that ACE2 activation
may play a role in improving efficacy of endothelial progenitor cell-based therapy in vascular injury by blunting the
Nox4/ROS system [144].
ACE2 and Ang-(1-7) further influence the redox state by regulating antioxidant enzymes, including superoxide
dismutase (SOD) and Nrf2. Infusion of recombinant human ACE2 (GSK2586881) in patients with pulmonary hyper-
tension was associated with increased plasma levels of SOD2 and reduced oxidative stress [91]. Similarly, in a mouse
model of bleomycin-induced pulmonary hypertension, recombinant ACE2 treatment increased pulmonary SOD2
expression, reduced oxidative stress and attenuated development of vascular remodelling [148]. Protective effects of
Ang-(1-7) in Ang II-induced cardiac hypertrophy involve Sirt-3 mediated deacetylation of Foxo3a, up-regulation
of SOD2 and decreased ROS levels in cardiomyocytes [149]. ACE2/Ang-(1-7) also modulates the transcription fac-
tor Nrf2, the master regulator of antioxidant genes. Endothelial cell senescence is attenuated by Ang-(1-7) through
pathways that involve Klotho and Nrf2 [119,150]. In models of hyperoxic lung injury, ACE2 activation inhibited
inflammation, reduced oxidative stress and activated the Nrf2 antioxidant pathway [150].
Another mechanism whereby ACE2/Ang-(1-7) modulates the oxidative milieu involves a novel nuclear system.
In renal cells Ang II-induced ROS production is attenuated by activation of nuclear ACE2/Ang-(1-7) [151]. The
functional significance of the nuclear system remains unclear, but it may act as a protective mechanism to prevent
accumulation of injurious ROS within the nucleus thereby preventing oxidative DNA damage [151].
Interactions between ACE2/Ang-(1-7)/Mas1 and AT2
receptors
Similar to Mas1, activation of AT2R mediates vasoprotective effects by promoting vasodilation and inhibiting inflam-
mation, fibrosis and apoptosis [152]. Growing evidence indicates that these G protein-coupled receptors interact, es-
pecially in the kidney, and that they heterodimerize [153–155]. AT2 and Mas1 receptors co-localize in the renal cortex
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of obese Zucker rats and are independently involved in the production of NO and the regulation of the natriuretic re-
sponse [154]. In astrocytes, Mas1 and AT2R heterodimerize and are functionally dependent on each other [155]. The
biological significance of Mas1:AT2R receptor dimerization remains unclear but interaction between these receptors
may amplify signaling and vasoprotective properties.
In addition to physical links between Mas1 and AT2R, cross-talk between these receptors may be mediated by
a common ligand, Ang-(1-7). This is supported by studies demonstrating that A779 as well as PD123319 (AT2R
antagonist) prevent Ang-(1-7) cellular and vascular actions [153,156]. The inhibitory effects of A779 are well de-
scribed. In mouse hearts pre-treated with the AT1R blocker losartan, PD123319 prevented Ang-(1-7) induced va-
sodilation and increased perfusion pressure [153]. Other studies demonstrated that PD123319 inhibits protective
effects of Ang-(1-7) in models of endothelial dysfunction [157,158], hepatocellular carcinoma [159], atherosclerosis
[160], ischaemic stroke [161], and cerebral autophagy in SHR [162]. However, some studies failed to show a role for
AT2R in Ang-(1-7)-mediated effects supporting Mas1 as the primary receptor for the peptide [163,164].
Interactions between ACE2, Ang-(1-7), Mas1 and AT2R have pathophysiological significance. In experimental
models of pulmonary hypertension, activation of the ACE2/Ang-(1-7)/Mas1 axis attenuates progression of disease,
processes associated with upregulation of AT2R [165]. Further supporting this notion, chronic treatment with com-
pound 21 (AT2R agonist) prevented cardiopulmonary fibrosis and attenuated pulmonary hypertension with an asso-
ciated increase in mRNA expression of ACE2 and Mas1 indicating that beneficial effects of AT2R activation involve
the ACE2-Ang-(1-7)-Mas1 pathway [166]. On the other hand, activation of ACE2/Ang-(1-7) increases expression of
AT2R in models of SHR, diabetes, Ang II-induced hypertension and pulmonary hypertension [167–170].
SARS-CoV-2 and COVID-19 implications of vascular ACE2
Beyond its vasoprotective functions, vascular ACE2 may play an important role in cardiovascular disease related to
COVID-19, since ACE2 is the receptor through which SARS-CoV-2 enters host cells causing infection [20–23].
ACE2 as the cell entry receptor for SARS-CoV-2
Viral infection studies in various ACE2 expressing cell types across species (human, bats, civet, pigs, mice), computa-
tional modelling and cryo-EM experiments demonstrated unambiguously that ACE2 is the receptor for SARS-CoV-2,
similar to that for other coronaviruses including SARS-CoV and middle east respiratory syndrome coronavirus
(MERS-CoV) [171]. Entry of SARS-CoV-2 into host cells depends on binding with the receptor via the virus sur-
face spike proteins (S-proteins), of which there are 2: the S1-protein possesses a receptor-binding domain (RBD) re-
sponsible for viral binding to the host cell and the S2-protein, which contains a fusion peptide domain important for
virus:host cell membrane fusion [172]. ACE2, as the cell entry receptor, is probably the key factor determining host cell
tropism and infectivity. While ACE2 normally localizes on the plasma membrane with the extracellular N-terminal
possessing the catalytic site for generation of Ang-(1-7) (and other peptides), it can undergo proteolytic shedding and
post-translational modification by various proteases and enzymes, including transmembrane protease serine 2 (TM-
PRSS2), disintegrin and metalloproteinase domain-containing protein (ADAM)10, ADAM17 (also called TACE),
cathepsins and furin [173,174]. Binding of SARS-CoV-2 via the S-protein to ACE2 prompts cleavage of ACE2 by
ADAM17/TACE at the extracellular N-tail, which possesses catalytic activity, producing soluble ACE2 [26], while
TMPRSS2 causes proteolytic cleavage of ACE2 at the intracellular C-domain without catalytic activity [23]. TM-
PRSS2, together with cathepsin B and L, primes ACE2 facilitating membrane fusion and internalization of the S
protein:ACE2 complex, essential for host cell infection [23].
Numerous accessory proteins have been identified that may influence viral release, stability and virulence. The
3-terminus of the SARS-CoV-2 genome encodes eight accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b and ORF14) which
play important roles in the entry of SARS-CoV-2 [175]. SARS-CoV-2 S-protein 1 has also been shown to bind CD147
a transmembrane glycoprotein of the immunoglobulin superfamily [176], which was previously shown to facilitate
SARS-CoV:host cell infection [177]. The complex regulatory processes of SARS-CoV-2:ACE2 interaction have been
described in recent publications and the reader is referred to these for further details [21–23].
SARS-CoV-2 and vascular ACE2
Vascular cells express many of the proteases involved in SARS-CoV-2-induced ACE2 post-translational modifica-
tion, suggesting potential viral infection in the vasculature. ACE2 together with TMPRSS2, ADAM10, ADAM17 and
cathepsins have been demonstrated in endothelial cells, although levels of ACE2 and TMPRSS2 are lower than in
nasal epithelium [178]. Cardiovascular cells also express CD147 and may play a role in severity of COVID-19 disease
in the elderly [178]. Despite increasing evidence that vascular ACE2 is involved in SARS-CoV-2-induced vascular
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injury, whether vascular cells are directly infected by the virus through endothelial or vascular smooth muscle cell
ACE2 still needs to be unambiguously proven, especially in the clinical context.
Translating SARS-Cov-2:ACE2 experimental evidence to the clinic has been challenging. This may relate, in part,
to the fact that murine and human ACE2 exhibit some differences with interspecies homology of 81.86% [179]. Both
murine and human ACE2 possess collectrin and peptidase M2 domains but amino acid sequences differ in the do-
main to which the S1-protein binds. Amino acids Asp30, His34, Tyr41, Gln42, Lys353, Arg357, Gln24 and Met82 of
human ACE2 play an important role in binding with viral S-protein [21]. Comparison of murine and human ACE2
sequences indicated that five out of these eight residues differ between the species [179]. These findings prompted
the development of humanized ACE2 mice (which possess the human ACE2 amino acid sequence) for investigating
SARS-CoV-2 pathology in the context of human disease [180].
Vascular ACE2 and the pathophysiology of COVID-19-related
cardiovascular disease
While COVID-19 is a viral disease of the respiratory system causing severe and progressive lung damage, it is also asso-
ciated with significant cardiovascular comorbidities and sequelae [181–183]. In particular, hypertension and diabetes
mellitus are major comorbidities of COVID-19, which itself predisposes to thromboembolic disease, acute myocardial
injury, myocarditis, heart failure and arrhythmias [182,183]. Patients with COVID-19 who have pre-existing cardio-
vascular disease have more severe disease and worse outcomes than those without a history of cardiovascular disease
[181,182,184,185]. The pathophysiological processes underlying COVID-19-related cardiovascular disease remain
unclear, but the vascular RAS system probably plays an important role. In the lungs and other organs, vascular injury
and loss of endothelial integrity cause tissue oedema, activation of coagulation pathways, inflammation, endotheliitis
and vascular dysfunction, processes contributing to tissue damage and organ failure in COVID-19 [184,186,187].
At the molecular level, vascular ACE2 may be critical (Figure 4). Firstly, SARS-CoV-2 binding to vascular ACE2
may facilitate virus entry into endothelial and vascular smooth muscle cells causing viral infection of the endothe-
lium and vascular media [188]. This probably involves other players as well, such as TMPRSS2 [23]. Post-mortem
analysis of different organs in patients with COVID-19 demonstrated endothelial cell viral infection and endothe-
liitis [188]. Secondly, down-regulation of vascular ACE2 by SARS-CoV-2 may decrease ACE2 activity leading to
reduced production of vasoprotective Ang-(1-7) causing endothelial dysfunction and increased vascular permeabil-
ity [187]. SARS-CoV has been shown to downregulate myocardial ACE2 in patients with severe acute respiratory
syndrome [189], and similar process may occur for SARS-CoV-2. Finally, viral infection and down-regulation of
the ACE2-Ang-(1-7) pathway could promote increased generation of vascular-derived cytokines and vasoactive fac-
tors causing endotheliitis, vascular inflammation and impaired vascular tone [189,190]. Although these processes
are plausible and vascular ACE2 might be pivotal in cardiovascular sequelae associated with COVID-19, this awaits
confirmation.
Targeting ACE2/Ang-(1-7)/Mas1 and AT2R as potential therapeutic
approaches in COVID-19
Considering the importance of ACE2 in cardiovascular (patho)physiology, it has been suggested that the loss of ACE2
catalytic function and dysregulation of the RAS may be responsible for the cardiovascular symptoms reported in
COVID-19 patients [181–183,186]. Accordingly, there is growing interest in targeting ACE2, as well as other RAS el-
ements especially Ang-(1-7)/Mas1 and AT2R, as therapeutic strategies in COVID-19 [191]. Studies have suggested (i)
ACE2 inhibitors to prevent viral entry, (ii) ACE2 activators to promote Ang-(1-7) anti-inflammatory actions and (iii)
soluble human recombinant ACE2 (shrACE2) to saturate and inactivate circulating S-protein, as putative novel thera-
peutic modalities to prevent SARS-CoV-2 infection of host cells [191–195]. In vitro studies have shown that shrACE2
decreases SARS-CoV-2 infection and clinical trials using shrACE2 (APN01) are currently underway [194,195] (Clin-
icalTrials.gov identifier NCT04335136). Other clinical trials targeting Ang-(1-7) (ATCO trial) and Mas1 (Clinical-
Trials.gov identifier NCT04332666; 04401423; 04375124) are also in progress. In addition, the AT2R agonist VP01
(C21) is being tested as a potential repurposed therapeutic in COVID-19 in the Angiotensin II Type Two Recep-
tor Agonist Covid-19 Trial (ATTRACT) (ClinicalTrials.gov identifier NCT04452435). Outcomes from these clinical
trials are awaited.
Conclusions
Vascular function is tightly regulated by the RAS. While the molecular biology, biochemistry and physiology of Ang
II are well defined, there is a paucity of information about the vascular ACE2/Ang-(1-7) system, especially in human
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Figure 4. Putative role of vascular ACE2 in cardiovascular disease associated with COVID-19
Since vascular cells express ACE2, it may be possible that SARS-CoV-2 interaction with vascular ACE2 plays a role in cardiovas-
cular disease associated with COVID-19. SARS-CoV-2 via its spike protein, which is primed by the endogenous transmembrane
serine protease 2 (TMPRSS2), binds to ACE2 for cell entry. The virus is endocytosed leading to fusion of viral and cellular mem-
branes and subsequent release of viral RNA into the cytosol which causes viral infection and the down-regulation of endogenous
ACE2 and up-regulation of ADAM17. Following the vesicular transport to the cell surface, ADAM17 cleaves the extracellular do-
main of ACE2 and takes part in processing of different cytokines leading to activation of inflammatory signalling which further
down-regulates vascular ACE2. Down-regulation in vascular ACE2 may lead to decreased Ang-(1-7) production contributing to
endotheliitis, vascular inflammation and impaired vascular tone, which could promote cardiovascular complications in COVID-19.
ACE2, angiotensin converting enzyme 2; ADAM17, tumour necrosis factor-alpha-converting enzyme; SARS-CoV-2, severe acute
respiratory syndrome coronavirus 2.
health and disease. It is becoming increasingly apparent that ACE2, through Ang-(1-7)/Mas, is vasoprotective and
that down-regulation of ACE2 promotes vascular injury and remodelling, processes that are ameliorated when ACE2
or Ang-(1-7) are up-regulated. Vascular ACE2 is controlled by humoral and mechanical factors and upon ADAM17
activation is shed from endothelial cells into the plasma, where circulating soluble ACE2 might be a predictive marker
of vascular health or disease. ACE2 is also regulated by drugs that inhibit the RAS. ACEi and ARBs increase expression
of ACE2 and may influence soluble ACE2 activity. Beyond its vasoprotective role in the cardiovascular system, ACE2
is crucially involved in the pathophysiology of COVID-19 as the receptor for SARS-CoV-2. COVID-19 is increas-
ingly being considered as an endothelial and vascular disease. Considering the importance of ACE2 in endothelial and
vascular cells, we speculate that vascular ACE2 may play a role in the cardiovascular risk factors and complications
of COVID-19. However, this awaits confirmation. Vascular ACE2 is emerging as a major regulatory system poten-
tially involved in many pathologies. It is therefore not surprising that the ACE2/Ang-(1-7)/Mas1 system is gaining
enormous interest as a therapeutic target.
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9 Lemarié, C. and Schiffrin, E. (2009) The angiotensin II type 2 receptor in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 11, 19–31,
https://doi.org/10.1177/1470320309347785
10 Nguyen, D.C.A. and Touyz, R (2011) A new look at the renin-angiotensin system— Focusing on the vascular system. Peptides 32, 2141–2150,
https://doi.org/10.1016/j.peptides.2011.09.010
11 Savoia, C., Burger, D., Nishigaki, N., Montezano, A. and Touyz, R. (2011) Angiotensin II and the vascular phenotype in hypertension. Expert Rev. Mol.
Med. 13, e11, https://doi.org/10.1017/S1462399411001815
12 Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N. et al. (2000) Novel angiotensin-converting enzyme-related
carboxypeptidase (ACE2) converts Angiotensin I to Angiotensin 1-9. Circ. Res. 87, 5, https://doi.org/10.1161/01.RES.87.5.e1
13 Mendoza-Torres, E., Oyarzún, A., Mondaca-Ruff, D., Azocar, A., Castro, P.F., Jalil, J.E. et al. (2015) ACE2 and vasoactive peptides: novel players in
cardiovascular/renal remodelling and hypertension. Ther. Adv. Cardiovasc Dis. 9, 217–237, https://doi.org/10.1177/1753944715597623
14 Danilczyk, U. and Penninger, J. (2006) Angiotensin-Converting Enzyme II in the heart and the kidney. Cir. Res. 98, 463–471,
https://doi.org/10.1161/01.RES.0000205761.22353.5f
15 Reudelhuber, T. (2006) A place in our hearts for the lowly Angiotensin 1-7 peptide? Hypertension 47, 811–815,
https://doi.org/10.1161/01.HYP.0000209020.69734.73
16 Santos, R. (2014) Angiotensin-(1-7). Hypertension 63, 1138–1147, https://doi.org/10.1161/HYPERTENSIONAHA.113.01274
17 Pereira, M., Souza, L., Becari, C., Duarte, D., Camacho, F., Oliveira, J. et al. (2013) Angiotensin II-Independent Angiotensin-(1-7) formation in rat
hippocampus. Hypertension 62, 879–885, https://doi.org/10.1161/HYPERTENSIONAHA.113.01613
400 © 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons








 Library user on 29 January 2021
Clinical Science (2021) 135 387–407
https://doi.org/10.1042/CS20200480
18 Santos, R., e Silva, A., Maric, C., Silva, D., Machado, R., de Buhr, I. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled
receptor Mas. Proc. Natl. Acad. Sci. U. S. A. 100, 8258–8263, https://doi.org/10.1073/pnas.1432869100
19 Tetzner, A., Gebolys, K., Meinert, C., Klein, S., Uhlich, A., Trebicka, J. et al. (2016) G-Protein-Coupled Receptor MrgD is a receptor for Angiotensin-(1-7)
involving Adenylyl Cyclase, cAMP, and Phosphokinase A. Hypertension 68, 185–194, https://doi.org/10.1161/HYPERTENSIONAHA.116.07572
20 Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.C., Turner, A.J. et al. (2020) Angiotensin-Converting Enzyme 2: SARS- CoV-2 receptor and
regulator of the Renin-Angiotensin System: Celebrating the 20th anniversary of the discovery of ACE2. Circ. Res. 126, 1456–1474,
https://doi.org/10.1161/CIRCRESAHA.120.317015
21 Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y. and Zhou, Q. (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science
367, 1444–1448, https://doi.org/10.1126/science.abb2762
22 Wan, Y., Shang, J., Graham, R., Baric, R. and Li, F. (2020) Receptor recognition by the novel coronavirus from Wuhan: an analysis based on
decade-long structural studies of SARS coronavirus. J. Virol. 94, 7, https://doi.org/10.1128/JVI.00127-20
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